Stability Testing for FDA Approved KSHNO14 (Pyridostigmine Bromide Extend – Release Tablets)

Name: Stability Testing for FDA Approved KSHNO14 (Pyridostigmine Bromide Extend – Release Tablets)
Creator: DEPT OF THE ARMY
Published: 2026-01-29T00:00:00+00:00
Keywords: CONTRACT

DEPT OF THE ARMYDEPT OF DEFENSE.DEPT OF THE ARMY.AMC.ACC.ACC-CTRS.ACC-APG.W6QK ACC-APG

AI Overview

Market research for FDA-compliant long-term stability testing of pyridostigmine bromide pharmaceutical tablets in support of ongoing CBRN medical countermeasure development.

This summary is AI-generated from the official solicitation.

Key Details

Agency

DEPT OF THE ARMY

Funding Amount

—

Release Date

January 29, 2026

Due Date

February 19, 2026 (Closed)

Official Description

This Sources Sought notice is issued for market research purposes only to identify potential sources capable of supporting FDA compliant stability testing for FDA approved KSHN014 (Pyridostigmine Bromide Extend – Release Tablets) 105 mg tablet for five (5) years at CRT and ten (10) years refrigerated, manufactured by Amneal Complex Research LLC and packaged in Blister Pack throughout the in-use period. The government is specifically seeking information on vendors capable of assuming or supporti...

View on official source

Change History

Opportunity AddedFeb 19, 2026 at 9:35 PM